Leiden University Testing Indicates Monepantel and Monepantel Sulphone SARS-CoV-2 Antiviral Activity

•  Previously PAA reported to shareholders that monepantel (MPL) and monepantel sulfone (MPLS) demonstrate antiviral activity in cultured cell infection models of SARSCoV-2, the virus causing COVID-19
•  Leiden University Medical Center (LUMC) has generated indicative data that MPL and MPLS again demonstrate antiviral activity in non-human primate systems
•  High insolubility of MPL in these systems was challenging and required several analyses
•  LUMC is now moving forward and transitioning to human cultured cells

DISC: I hold

Epichem Licensing Agreement to Develop Waste to Fuels Technology

•  Epichem has entered into a license agreement with Thermaquatica for the Oxidative Hydrothermal Dissolution (OHD) technology
•  Epichem will research, develop and promote the novel, innovative, disruptive technology using Flow Reaction
•  Epichem will continue to seek government and project grant funding to accelerate the initiative

...Epichem OHD will advance the novel, disruptive and innovative OHD technology using biomass/feedstock flow reactor material science. The flow reactor is a world-first with its potential to turn a wide range of waste and biomass feedstock into valuable fuels, fine chemicals, agricultural growth stimulants and ethanol....

The flow reactor has the potential to convert:

•  Plastics into renewable fuels
•  Coal into diesel or agricultural biostimulants (diesel, fine chemicals and biostimulants)
•  Rubber tyres into liquid fuels/valuable chemical products
•  Trees into cellulosic ethanol/fine chemicals
•  Leftover stock or crops into liquid fuel – cellulosic ethanol and agricultural biostimulants.

Disc: I hold...bought as a SC Health Stock...only a month ago they called themselves "a clinical stage oncology company". Also Scherobi added a post "History" a month ago

Still very happy to hold 

Phase IIb Clinical Trial Studying Monepantel in Pet Dogs with Treatment Naïve B Cell Lymphoma

~ Recruitment for the trial has commenced

~ Several dogs have already been successfully recruited and have started treatment with MPL tablets

~ Six pet dogs currently treated on a compassionate basis with MPL tablets

15 February 2021 – Perth, Australia: PharmAust Ltd (ASX:PAA), a clinical-stage oncology company, is pleased to provide an update on its Phase IIb trial testing the effects of monepantel upon pet owners’ dogs with treatment naïve B cell lymphoma.

Recruitment for the trial has commenced and several dogs have been successfully recruited and have started treatment with MPL tablets.

Six dogs not eligible for the trial have commenced compassionate treatment with MPL tablets.

PharmAust will be pleased to update the market when a sufficient number of dogs with meaningful trial endpoints have completed their treatment regimen

Disc: I hold

Update: Monepantel COVID-19 Testing in the Netherlands

~ Leiden University continues to evaluate monepantel in their anti-Covid19 systems

~ Experimental work affected by global supply chain shortages

~ Timing not affecting PharmAust’s overall clinical development plans

 PharmAust Ltd (ASX:PAA), a clinical-stage oncology company, is pleased to provide further information on work being conducted in the Netherlands investigating the effects of monepantel upon coronavirus infections.

The coronavirus pandemic has been severely affecting global supply chains and consequently performing experiments in many parts of the world, including the Netherlands, has proven problematic. Tests using monepantel and monepantel sulfone as Covid-19 antivirals, however, continue at Leiden University and PharmAust will be pleased to update the market when results come to hand.

DISC: I hold